Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6115588 | Diagnostic Microbiology and Infectious Disease | 2015 | 15 Pages |
Abstract
The activity of ceftolozane/tazobactam was tested against 50 nonduplicate Pseudomonas aeruginosa from 18 cystic fibrosis children collected in 2012-2014. These isolates were multidrug resistant with susceptibility to meropenem, ceftazidime, and piperacillin/tazobactam of 46%, 58%, and 50%, respectively. Ceftolozane/tazobactam was the most active with MIC50, MIC90, and percent susceptibility of 2Â mg/L, 8Â mg/L, and 86%.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Joseph L. Kuti, Rebecca S. Pettit, Natalie Neu, Jeffrey J. Cies, Craig Lapin, Marianne S. Muhlebach, Kimberly J. Novak, Sean T. Nguyen, Lisa Saiman, David P. Nicolau,